Chronic PainDepressive DisordersAnxiety DisordersSubstance Use Disorders (SUD)Headache Disorders (Cluster & Migraine)Safety & Risk ManagementImmunology & Inflammation

Chronic pain and psychedelics: a review and proposed mechanism of action

This review synthesises clinical and mechanistic evidence suggesting classic psychedelics — via 5‑HT2A receptor agonism and resultant changes in brain functional connectivity — may reverse neural alterations underlying chronic pain and produce analgesic effects, with limited but promising reports in cancer pain, phantom limb pain and cluster headache. Given their comparatively favourable safety profile versus opioids, the authors propose further clinical research into psychedelics as non‑opioid analgesics.

Authors

  • Castellanos, J. P.
  • Woolley, C.
  • Bruno, K. A.

Published

Regional Anesthesia and Pain Medicine
meta Study

Abstract

The development of chronic pain is a complex mechanism that is still not fully understood. Multiple somatic and visceral afferent pain signals, when experienced over time, cause a strengthening of certain neural circuitry through peripheral and central sensitization, resulting in the physical and emotional perceptual chronic pain experience. The mind-altering qualities of psychedelics have been attributed, through serotonin 2A (5-HT2A) receptor agonism, to ‘reset’ areas of functional connectivity (FC) in the brain that play prominent roles in many central neuropathic states. Psychedelic substances have a generally favorable safety profile, especially when compared with opioid analgesics. Clinical evidence to date for their use for chronic pain is limited; however, several studies and reports over the past 50 years have shown potential analgesic benefit in cancer pain, phantom limb pain and cluster headache. While the mechanisms by which the classic psychedelics may provide analgesia are not clear, several possibilities exist given the similarity between 5-HT2A activation pathways of psychedelics and the nociceptive modulation pathways in humans. Additionally, the alterations in FC seen with psychedelic use suggest a way that these agents could help reverse the changes in neural connections seen in chronic pain states. Given the current state of the opioid epidemic and limited efficacy of non-opioid analgesics, it is time to consider further research on psychedelics as analgesics in order to improve the lives of patients with chronic pain conditions.

Available with Blossom Pro

Research Summary of 'Chronic pain and psychedelics: a review and proposed mechanism of action'

Introduction

Psychedelics are psychoactive compounds that alter perception and consciousness and have a long history of ceremonial and medicinal use across cultures. Recent decades have seen a resurgence of clinical interest, driven by improved research methods and promising findings for psychiatric indications such as depression, anxiety and addiction. There is also growing, though limited, evidence that classic serotonergic psychedelics may produce antinociceptive effects in certain chronic pain conditions. Chronic pain development is described as a multifactorial process in which prolonged somatic and visceral nociceptive input produces peripheral and central sensitization and consequent durable changes in pain perception. This review sets out to examine the historical context, safety profile and pharmacologic classification of psychedelic compounds and to discuss potential mechanisms by which they might affect chronic pain. Castellanos and colleagues frame the review around molecular actions (especially at the serotonin-2A, 5-HT2A, receptor), downstream effects on gene expression and inflammation, and alterations in brain functional connectivity (FC) that could plausibly reverse or remodel the neural changes seen in chronic pain states. The authors aim to synthesise clinical reports and basic science to motivate focused future research on psychedelics as analgesics.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (29)

Papers cited by this study that are also in Blossom

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

Psychedelics as Medicines: An Emerging New Paradigm

Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)

Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF)

Ramachandran, V., Chunharas, C., Marcus, Z. et al. · Neurocase (2018)

Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Taking Psychedelics Seriously

Byock, I. · Journal of Palliative Medicine (2018)

Do hallucinogens cause residual neuropsychological toxicity?

Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (1999)

71 cited
Psychological and cognitive effects of long-term peyote use among Native Americans

Halpern, J. H., Sherwood, A. R., Hudson, J. I. et al. · Biological Psychiatry (2005)

Show all 29 references
Hallucinogens

Nichols, D. E. · Pharmacology and Therapeutics (2004)

Adverse Reactions to Psychedelic Drugs - A Review of the Literature

Strassman, R. J. · Journal of Nervous and Mental Disease (1984)

273 cited
Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

Halberstadt, A. L. · Current Topics in Behavioral Neurosciences (2017)

116 cited
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Lysergic acid diethylamide: side effects and complications

Cohen, S. · Journal of Nervous and Mental Disease (1980)

Psychedelics and connectedness

Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)

Psychedelic Drugs in Biomedicine

Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)

818 cited
Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial

Galvão-Coelho, N. L., de Almeida, R. N., de Menezes Galvão, A. C. et al. · Frontiers in Psychology (2019)

Altered network hub connectivity after acute LSD administration

Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)

142 cited
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)

229 cited
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Schindler, E. A. D., Gottschalk, C. H., Weil, M. J. et al. · Journal of Psychoactive Drugs (2015)

91 cited

Cited By (21)

Papers in Blossom that reference this study

Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study

Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis

Kopra, E., Cleare, A. J., Rucker, J. et al. · Journal of Affective Disorders (2022)

Microdosing psilocybin for chronic pain: a case series

Lyes, M., Yang, K. H., Castellanos, J. P. et al. · PAIN (2022)

Naturalistic Psychedelic Use: A World Apart from Clinical Care

Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)

Show all 21 papers
21 cited
LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

Wießner, I., Olivieri, R., Falchi, M. et al. · European Neuropsychopharmacology (2022)

Beating Pain with Psychedelics: Matter over Mind?

Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)

Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia

Glynos, N. G., Pierce, J., Davis, A. K. et al. · Journal of Psychoactive Drugs (2022)

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

A narrative synthesis of research with 5-MeO-DMT

Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)

Psychedelic mushrooms in the USA: Knowledge, patterns of use and association with health outcomes

Matzopoulos, R., Morlock, A., Morlock, R. et al. · MedRvix (2021)

The effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies

Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Corrigan, K., Haran, M., Mccandliss, C. et al. · Irish Journal of Medical Science (2021)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.